Biologics

Rion, a regenerative medicine company, named five leaders to its advisory board, according to a Sept. 25 news release.

Zetagen Therapeutics' ZetaFuse has potential to treat degenerative disc disease in patients with late-stage cancer, according to a case study in the Journal of the American Academy of Orthopaedic Surgeons.

Cerapedics earned FDA approval to expand the use of its spinal fusion biologic, i-Factor P-15, according to a Sept. 24 news release.

Here are five companies making spine and orthopedic biologic products:

Bone marrow aspirate injections didn't lead to significant changes for patients who had  arthroscopic partial meniscectomy, according to a Sept. 15 study in The American Journal of Sports Medicine.

Spine biologics is a realm ripe for exploration of its potential and applications in patient care.

Regenerative medicine in spine surgery is on the rise, and there are many biologic tools that physicians say could be used more in the field.

Temple Therapeutics, a women's health company, launched a spinoff venture for orthopedic sports medicine, according to a Sept. 9 news release.  

Growing biologics portfolios will play a key role in pushing the spine surgery device market in the coming years, according to a report from Coherent Market Insights.

From product debuts and approvals, here are four key updates from orthobiologic companies since June 4.